产品
编 号：F341458
分子式：C20H25N3O4
分子量：371.43
分子式：C20H25N3O4
分子量：371.43
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 378746-64-6
产品详情
生物活性：
Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
体内研究：
Nemonoxacin (p.o.; 15 min and 6 h after infection) shows potent and broad-spectrum in vivo activity against both Gram-positive (S. aureus, S. capitis, S. pneumonia and E. faecalis) and Gram-negative (E. coli) isolates.Nemonoxacin (p.o.; 6, 12 and 24 h after infection) shows potent activities towards (2.5, 5, 10, 20 mg/kg) S. pneumonia 0613 (PRSP) and (10, 20, 40, 80 mg/kg) K. pneumonia 0607 infections in mouse pulmonary infection model.Animal Model:CD-1 ICR mice (18-22 g; mouse systemic infection model).
Dosage:1.6-4.0 mg/kg (S. aureus and S. capitis infections), 2.4-10.0 mg/kg (S. pneumonia infections), 5.0-22.6 mg/kg (E. faecalis infections), 1.6-10.0 mg/kg (E. coli infections)
Administration:Oral administration; 15 min and 6 h after infection
Result:Showed the ED50s of 2.08, 2.59 and 2.52 mg/kg to against S. aureus ATCC 29213 (MSSA), S. aureus 0705 (MRSA) and S. capitis 0687 (levofloxacin-resistant MRSC), respectively.
Animal Model:CD-1 ICR mice (18-22 g; mouse pulmonary infection model).
Dosage:2.5, 5, 10, 20 mg/kg (S. pneumonia 0613 (PRSP)); 10, 20, 40, 80 mg/kg (K. pneumonia 0607)
Administration:Oral administration; 6, 12 and 24 h after infection
Result:Significantly decreased colony counts in vivo.
体外研究：
Nemonoxacin (0-5.51 μM; 24 h) shows good antibacterial activity in vitro.
Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
体内研究：
Nemonoxacin (p.o.; 15 min and 6 h after infection) shows potent and broad-spectrum in vivo activity against both Gram-positive (S. aureus, S. capitis, S. pneumonia and E. faecalis) and Gram-negative (E. coli) isolates.Nemonoxacin (p.o.; 6, 12 and 24 h after infection) shows potent activities towards (2.5, 5, 10, 20 mg/kg) S. pneumonia 0613 (PRSP) and (10, 20, 40, 80 mg/kg) K. pneumonia 0607 infections in mouse pulmonary infection model.Animal Model:CD-1 ICR mice (18-22 g; mouse systemic infection model).
Dosage:1.6-4.0 mg/kg (S. aureus and S. capitis infections), 2.4-10.0 mg/kg (S. pneumonia infections), 5.0-22.6 mg/kg (E. faecalis infections), 1.6-10.0 mg/kg (E. coli infections)
Administration:Oral administration; 15 min and 6 h after infection
Result:Showed the ED50s of 2.08, 2.59 and 2.52 mg/kg to against S. aureus ATCC 29213 (MSSA), S. aureus 0705 (MRSA) and S. capitis 0687 (levofloxacin-resistant MRSC), respectively.
Animal Model:CD-1 ICR mice (18-22 g; mouse pulmonary infection model).
Dosage:2.5, 5, 10, 20 mg/kg (S. pneumonia 0613 (PRSP)); 10, 20, 40, 80 mg/kg (K. pneumonia 0607)
Administration:Oral administration; 6, 12 and 24 h after infection
Result:Significantly decreased colony counts in vivo.
体外研究：
Nemonoxacin (0-5.51 μM; 24 h) shows good antibacterial activity in vitro.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备